Efficacy of repeated high-dose hepatitis B vaccine (80 μg) in patients with chronic liver disease
A rapid real-time PCR assay for determination of hepatitis C virus genotypes 1, 2 and 3a
Modulation of the anti-inflammatory interleukin 10 and of proapoptotic IL-18 in patients with chronic hepatitis C treated with interferon alpha and ribavirin
Comparison of hepatitis C treatment patterns in patients with and without psychiatric and/or substance use disorders†
Black patients with chronic hepatitis C have a lower sustained viral response rate than non-Blacks with genotype 1, but the same with genotypes 2/3, and this is not explained by more frequent dose reductions of interferon and ribavirin*
Switching to adefovir monotherapy after emergence of lamivudine-resistant mutations in patients with liver cirrhosis
Safety and efficacy of lamivudine in patients with severe acute or fulminant hepatitis B, a multicenter experience
Clinical pathways for patients with newly diagnosed hepatitis C – What actually happens
Is hepatitis C virus a risk factor for thyroid autoimmunity?
A prospective study of the evolution of lamivudine resistance mutations in patients with chronic hepatitis B treated with lamivudine